Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

[Gastrointestinal dysfunction has important implications for plasma L-dopa concentrations in Parkinson's disease].

Doi H, Sakakibara R, Kishi M, Tsuyuzaki Y, Tateno F, Hirai S.

Rinsho Shinkeigaku. 2013;53(11):1382-5. Review. Japanese.

PMID:
24291998
2.

Is there a difference in gastric emptying between Parkinson's disease patients under long-term L-dopa therapy with and without motor fluctuations? An analysis using the 13C-acetate breath test.

Tanaka Y, Kato T, Nishida H, Araki H, Murase M, Nagaki M, Moriwaki H, Inuzuka T.

J Neurol. 2009 Dec;256(12):1972-6. doi: 10.1007/s00415-009-5220-5.

PMID:
19575260
3.

Gastric emptying time and gastric motility in patients with Parkinson's disease.

Hardoff R, Sula M, Tamir A, Soil A, Front A, Badarna S, Honigman S, Giladi N.

Mov Disord. 2001 Nov;16(6):1041-7.

PMID:
11748735
4.

Levodopa delivery systems: advancements in delivery of the gold standard.

Ngwuluka N, Pillay V, Du Toit LC, Ndesendo V, Choonara Y, Modi G, Naidoo D.

Expert Opin Drug Deliv. 2010 Feb;7(2):203-24. doi: 10.1517/17425240903483166. Review.

PMID:
20095943
5.

Levodopa and 3-OMD levels in Parkinson patients treated with Duodopa.

Antonini A, Bondiolotti G, Natuzzi F, Bareggi SR.

Eur Neuropsychopharmacol. 2010 Oct;20(10):683-7. doi: 10.1016/j.euroneuro.2010.04.010. Epub 2010 May 31.

PMID:
20570113
6.

Increased gastric motility during 5-HT4 agonist therapy reduces response fluctuations in Parkinson's disease.

Asai H, Udaka F, Hirano M, Minami T, Oda M, Kubori T, Nishinaka K, Kameyama M, Ueno S.

Parkinsonism Relat Disord. 2005 Dec;11(8):499-502. Epub 2005 Nov 2.

PMID:
16263322
7.

Irregular gastrointestinal drug absorption in Parkinson's disease.

Nyholm D, Lennernäs H.

Expert Opin Drug Metab Toxicol. 2008 Feb;4(2):193-203. doi: 10.1517/17425255.4.2.193. Review.

PMID:
18248312
8.

Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease.

Napolitano A, Del Dotto P, Petrozzi L, Dell'Agnello G, Bellini G, Gambaccini G, Bonuccelli U.

Clin Neuropharmacol. 1999 Jan-Feb;22(1):24-9.

PMID:
10047930
9.

Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.

Adamiak U, Kaldonska M, Klodowska-Duda G, Wyska E, Safranow K, Bialecka M, Gawronska-Szklarz B.

Clin Neuropharmacol. 2010 May;33(3):135-41. doi: 10.1097/WNF.0b013e3181d47849.

PMID:
20216409
10.

Homocysteine levels after acute levodopa intake in patients with Parkinson's disease.

Müller T, Kuhn W.

Mov Disord. 2009 Jul 15;24(9):1339-43. doi: 10.1002/mds.22607.

PMID:
19425084
11.

Preventive effect of rikkunshito on gastric motor function inhibited by L-dopa in rats.

Wang L, Mogami S, Karasawa H, Yamada C, Yakabi S, Yakabi K, Hattori T, Taché Y.

Peptides. 2014 May;55:136-44. doi: 10.1016/j.peptides.2014.02.011. Epub 2014 Mar 11.

PMID:
24631952
12.

Plasma levodopa peak delay and impaired gastric emptying in Parkinson's disease.

Doi H, Sakakibara R, Sato M, Masaka T, Kishi M, Tateno A, Tateno F, Tsuyusaki Y, Takahashi O.

J Neurol Sci. 2012 Aug 15;319(1-2):86-8. doi: 10.1016/j.jns.2012.05.010. Epub 2012 May 25.

PMID:
22632782
13.

Delayed gastric emptying in Parkinson's disease.

Marrinan S, Emmanuel AV, Burn DJ.

Mov Disord. 2014 Jan;29(1):23-32. doi: 10.1002/mds.25708. Epub 2013 Oct 21. Review.

PMID:
24151126
14.

A serotonin 5-HT1A receptor agonist prevents behavioral sensitization to L-DOPA in a rodent model of Parkinson's disease.

Tomiyama M, Kimura T, Maeda T, Kannari K, Matsunaga M, Baba M.

Neurosci Res. 2005 Jun;52(2):185-94. Epub 2005 Apr 13.

PMID:
15893579
15.

Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.

Nyholm D, Odin P, Johansson A, Chatamra K, Locke C, Dutta S, Othman AA.

AAPS J. 2013 Apr;15(2):316-23. doi: 10.1208/s12248-012-9439-1. Epub 2012 Dec 11.

16.

Reduced L-dopa absorption and increased clinical fluctuations in Helicobacter pylori-infected Parkinson's disease patients.

Pierantozzi M, Pietroiusti A, Sancesario G, Lunardi G, Fedele E, Giacomini P, Frasca S, Galante A, Marciani MG, Stanzione P.

Neurol Sci. 2001 Feb;22(1):89-91.

PMID:
11487216
17.

Ghrelin prevents levodopa-induced inhibition of gastric emptying and increases circulating levodopa in fasted rats.

Wang L, Murphy NP, Stengel A, Goebel-Stengel M, St Pierre DH, Maidment NT, Taché Y.

Neurogastroenterol Motil. 2012 May;24(5):e235-45. doi: 10.1111/j.1365-2982.2012.01904.x. Epub 2012 Mar 23.

18.

The long-duration action of levodopa may be due to a postsynaptic effect.

Barbato L, Stocchi F, Monge A, Vacca L, Ruggieri S, Nordera G, Marsden CD.

Clin Neuropharmacol. 1997 Oct;20(5):394-401.

PMID:
9331515
19.

The pharmacokinetic profile of the "first ever" oral dose of levodopa in de novo patients with Parkinson's disease.

Djaldetti R, Rosmarin V, Ziv I, Melamed E.

Clin Neuropharmacol. 2001 Mar-Apr;24(2):95-8.

PMID:
11307044
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk